close

Agreements

Date: 2020-02-12

Type of information: Nomination

Compound: member of the board

Company: Sangamo Therapeutics (USA - CA)

Therapeutic area:

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On February 12, 2020,  Sangamo Therapeutics announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general management, manufacturing and technology experience at Merck, to the Sangamo Board of Directors. Dr. Markels has over 30 years of leadership experience in the pharmaceutical industry. He currently serves as President of Global Vaccines at Merck&Co, a role in which he leads an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio. Earlier roles at Merck included President, Latin America, as well as a long career in senior leadership positions in major regions worldwide in manufacturing technology, operations and strategy, business development, alliance management, and supply chain. Dr. Markels received his Ph.D. in chemical engineering from the University of California, Berkeley and his B.S. in chemical engineering from the University of Delaware.

Financial terms:

Latest news:

Is general: Yes